BioNTech and its partner Duality Biologics said they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca, and Daiichi Sankyo.
The European Union’s drug regulator will this week consider wider use of Novo Nordisk’s weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks.
U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly (LLY.N) plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters.
Sun Pharma first moved to acquire Taro in May 2007, at the time offering $454 million or $7.75 per share.
“Would-be insider traders tempted by the prospect of easy money should know that the Southern District of New York is watching, we’ll catch you, and we’ll make sure you pay the price for violating the law,” stated Damian Williams, United States Attorney for the Southern District of New York.
A legislative proposal, if passed into law, could cost the United States up to 1.2 million jobs and lead to more than 130 fewer FDA approvals over a 10-year period.
The pharma companies may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.
The decision reinstates the U.S. International Trade Commission’s import ban and cease and desist order on Apple watches that were found to infringe Masimo’s patented pulse oximetry technology.
The Swiss pharma’s Phase III trial of ligelizumab in patients with peanut allergies has been terminated, according to a ClinicalTrials.gov update.
Eli Lilly’s Jaypirca (pirtobrutinib) is forecast to become the market leader in BTK inhibitors for CLL, garnering nearly 60% share with about $3 billion in sales by 2032, according to GlobalData.
